Commentary: Early failure of the Trifecta GT bioprosthesis: Innovation is not always progress

Central MessageThere is an urgent need to elucidate all possible mechanisms of early and late prosthetic valve failure, especially as treatment options for severe aortic stenosis continue to rapidly evolve.See Article page 106. There is an urgent need to elucidate all possible mechanisms of early and late prosthetic valve failure, especially as treatment options for severe aortic stenosis continue to rapidly evolve. See Article page 106. Structural valve degeneration (SVD) is a major disadvantage of surgical aortic valve replacement (AVR) with a bioprosthesis. A recent single-center series demonstrated that the Trifecta valve (Abbott Vascular, Santa Clara, Calif) can be safely implanted in the aortic position with excellent hemodynamics and midterm durability,1Kilic A. Sultan I. Navid F. Aranda-Michel E. Chu D. Thoma F. et al.Trifecta aortic bioprosthesis: midterm results in 1,953 patients from a single center.Ann Thorac Surg. 2019; 107: 1356-1362Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar whereas others have shown unusually high early SVD rates with this prosthesis.2Fukuhara S. Shiomi S. Yang B. Kim K. Bolling S.F. Haft J. et al.Early structural valve degeneration of trifecta bioprosthesis.Ann Thorac Surg. 2020; 109: 720-727Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar The newer-generation Trifecta with Glide Technology (GT) was designed to improve these results, using novel antileaflet calcification and anti-support strut distortion technology. In this issue of the Journal, Tchouta and colleagues3Tchouta L. Liesman D. Kim K. Fukuhara S. Early failure of the Trifecta GT bioprostheses.J Thorac Cardiovasc Surg Tech. 2020; 4: 106-108Google Scholar reported 3 cases of early SVD after AVR with the Trifecta GT, for a cumulative incidence of 3.3% at 3.5 years among a population of 106 patients. Mean age at implantation was 56.7 years and all 3 patients had bicuspid aortic valve. The SVD occurred between 1.9 and 3.2 years after implantation, and all patients presented with aortic insufficiency and heart failure. There was no patient–prosthesis mismatch and endocarditis. All patients underwent redo AVR, and intraoperative findings were similar in the 3 cases, namely a detached prosthetic leaflet at the stent post between the noncoronary and right coronary cusps, without leaflet calcification. The authors postulated that the externally mounted leaflet design of the Trifecta GT and mechanical abrasion from the aortic wall may have contributed to the early failure of the prosthesis. The report by Tchouta and colleagues3Tchouta L. Liesman D. Kim K. Fukuhara S. Early failure of the Trifecta GT bioprostheses.J Thorac Cardiovasc Surg Tech. 2020; 4: 106-108Google Scholar suggests that biologic/immunologic factors may be less relevant in early SVD, whereas the mechanical/fluid dynamic properties directly associated with particular elements of the prosthetic valve design may be more important contributing factors.2Fukuhara S. Shiomi S. Yang B. Kim K. Bolling S.F. Haft J. et al.Early structural valve degeneration of trifecta bioprosthesis.Ann Thorac Surg. 2020; 109: 720-727Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar,4Gallo M. Demertzis S. Xenoantigens and structural valve degeneration of Trifecta bioprosthesis: connecting the dots.Ann Thorac Surg. 2020; 110: 343Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar No prosthetic leaflet calcification was observed in any of the 3 cases. Conversely, the leaflet disinsertion found at the same location in all patients was also observed in a majority of the cases of SVD presenting with pure aortic insufficiency occurring on the first-generation Trifecta prosthesis.2Fukuhara S. Shiomi S. Yang B. Kim K. Bolling S.F. Haft J. et al.Early structural valve degeneration of trifecta bioprosthesis.Ann Thorac Surg. 2020; 109: 720-727Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar In vitro fluid dynamic studies have shown that the externally mounted design of the Trifecta valve is associated with favorable hemodynamic properties compared with other stented bioprostheses, in which leaflets are mounted internally, including a lower resistance to flow and a larger effective orifice area. However, a greater degree of prosthetic leaflet flutter was observed with the Trifecta prosthesis.5Marx P. Kowalczyk W. Demircioglu A. Shehada S.-E. Wendta H. Mourad F. et al.An in vitro comparison of flow dynamics of the Magna Ease and the Trifecta prostheses.Minim Invasive Ther Allied Technol. 2020; 29: 78-85Crossref PubMed Scopus (4) Google Scholar The Mitroflow valve (LivaNova Group Inc, London, England), another bioprosthesis in which the leaflets are externally-mounted, is well-known to have high rates of accelerated SVD.6Ius F. Schulz J. Roumieh M. Fleissner F. Ismail I. Tudorache I. et al.Long-term results of the Mitroflow aortic pericardial bioprosthesis in over 800 patients: limited durability and mechanisms of dysfunction.Eur J Cardiothorac Surg. 2017; 52: 264-271Crossref PubMed Scopus (24) Google Scholar Another hypothesis is that the asymmetrical aortic annulus of bicuspid aortic valve may have increased the likelihood of abnormal shear-stress patterns and may potentially explain the monomorphic nature of the observed prosthetic failures. The implant technique itself may have a major impact in the durability of prostheses with externally mounted leaflets, including oversizing, bending of the strut posts during hand-tying of sutures, or the use of suture-tying devices with rigid knot stabilizers. Although oversizing was unlikely to play a significant role in the SVD reported by Tchouta and colleagues,3Tchouta L. Liesman D. Kim K. Fukuhara S. Early failure of the Trifecta GT bioprostheses.J Thorac Cardiovasc Surg Tech. 2020; 4: 106-108Google Scholar 2 of the 3 patients required an aortic annulus enlargement, and the third was a female with small body surface area and aortic root diameter, suggesting anatomical conditions likely to favor strut distortion during implantation. In summary, the findings by Tchouta and colleagues3Tchouta L. Liesman D. Kim K. Fukuhara S. Early failure of the Trifecta GT bioprostheses.J Thorac Cardiovasc Surg Tech. 2020; 4: 106-108Google Scholar are concerning, especially given the current trend of extending bioprosthetic AVR to younger patients. Well-designed, multicenter studies are urgently needed to elucidate all possible mechanisms of early SVD, to allow for a fine-tuning of the surgical implant, and optimal selection of the appropriate prosthesis for each individual patient. The report by Tchouta and colleagues3Tchouta L. Liesman D. Kim K. Fukuhara S. Early failure of the Trifecta GT bioprostheses.J Thorac Cardiovasc Surg Tech. 2020; 4: 106-108Google Scholar further highlights the fact that close longitudinal echocardiographic surveillance becomes paramount in an era in which the treatment of severe aortic stenosis is rapidly evolving. Early failure of the Trifecta GT bioprosthesesJTCVS TechniquesVol. 4PreviewTrifecta bioprosthetic valves with Glide Technology, also known as Trifecta GT (Abbott Vascular, Santa Clara, Calif), were approved by the US Food and Drug Administration in 2016. These are stented valves with a bovine pericardial sheet externally mounted on a titanium stent. There were several reports of early failure involving the first-generation Trifecta that were related to structural valve degeneration secondary to leaflet calcification, pannus formation, and cusps tear presenting less than 7 years after implantation. Full-Text PDF Open Access

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.